Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects

Advanced age is associated with severe symptoms and death upon SARS-CoV-2 infection. Virus-specific CD8 + T-cell responses have shown to be protective toward critical COVID-19 manifestations, suggesting that suboptimal cellular immunity may contribute to the age-pattern of the disease. The induction...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 693054
Main Authors Gallerani, Eleonora, Proietto, Davide, Dallan, Beatrice, Campagnaro, Marco, Pacifico, Salvatore, Albanese, Valentina, Marzola, Erika, Marconi, Peggy, Caputo, Antonella, Appay, Victor, Gavioli, Riccardo, Nicoli, Francesco
Format Journal Article
LanguageEnglish
Published Frontiers 13.07.2021
Frontiers Media S.A
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Advanced age is associated with severe symptoms and death upon SARS-CoV-2 infection. Virus-specific CD8 + T-cell responses have shown to be protective toward critical COVID-19 manifestations, suggesting that suboptimal cellular immunity may contribute to the age-pattern of the disease. The induction of a CD8 + T-cell response against an emerging pathogen like SARS-CoV-2 relies on the activation of naive T cells. To investigate whether the primary CD8 + T-cell response against this virus is defective in advanced age, we used an in vitro approach to prime SARS-CoV-2-specific naive CD8 + T cells from healthy, unexposed donors of different age groups. Compared to younger adults, older individuals display a poor SARS-CoV-2-specific T-cell priming capacity in terms of both magnitude and quality of the response. In addition, older subjects recognize a lower number of epitopes. Our results implicate that immune aging is associated with altered primary SARS-CoV-2-specific CD8 + T-cell responses.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMCID: PMC8315546
Reviewed by: Sarah Rowland-Jones, University of Oxford, United Kingdom; Elena Martinelli, Northwestern University, United States
These authors have contributed equally to this work
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Edited by: Pia Kvistborg, The Netherlands Cancer Institute (NKI), Netherlands
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.693054